ReviewRadiation oncology journal2016
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment.
Review in Radiation oncology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Frequency Survey of Brain Metastases and Its Associated Factors Among Iranian Women with Breast Cancer: A Cross-sectional Study in Tehran City.Galen medical journal · 2024Article
- Synthesis and characterization of actively HER-2 Targeted FeBioImpacts : BI · 2023Article
- Brain and heart-specific death in cancer patients: Population-based study.Cancer medicine · 2021Article
- The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.Investigational new drugs · 2020Article
- Clinical Perspectives in Brain Metastasis.Cold Spring Harbor perspectives in medicine · 2020Review
- Outcome of Omani Women with Breast Cancer-associated Brain Metastases Experience from a University Hospital.Oman medical journal · 2019Article
- Trastuzumab-Modified Gold Nanoparticles Labeled withNanomaterials (Basel, Switzerland) · 2019Article
- Central Nervous System Failure in Korean Breast Cancer Patients with HER2-Enriched Subtype: Korean Radiation Oncology Group 16-15 Multicenter Retrospective Study.Journal of breast cancer · 2019Article
- Brain metastasis in gastroesophageal adenocarcinoma and HER2 status.Journal of neuro-oncology · 2018Article
- Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.BMC cancer · 2018Article
- Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.Nuclear medicine and biology · 2018Article
- Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.International journal of oncology · 2018Article
- Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer.Chronic diseases and translational medicine · 2017Review
- Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy.Radiation oncology (London, England) · 2017Article
- Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.Oncotarget · 2016Article
- Practical consensus recommendations on Her2 +ve breast cancer with solitary brain mets.South Asian journal of cancerArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of human epidermal growth factor receptor 2 (HER2) is found in about 20% of breast cancer patients. With treatment using trastuzumab, an anti-HER2 monoclonal antibody, systemic control is improved. Nonetheless, the incidence of brain metastasis does not be improved, rather seems to be increased in HER2-positive breast cancer. The mainstay treatment for brain metastases is radiotherapy. According to the number of metastatic lesions and performance status of patients, radiosurgery or whole brain radiotherapy can be performed. The concurrent use of a radiosensitizer further improves intracranial control. Due to its large molecular weight, trastuzumab has a limited ability to cross the blood-brain barrier. However, small tyrosine kinase inhibitors such as lapatinib, has been noted to be a promising agent that can be used as a radiosensitizer to affect HER2-positive breast cancer. This review will outline general management of brain metastases and will focus on preclinical findings regarding the radiosensitizing effect of small molecule HER2 targeting agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.